Primary care clinicians play an essential role in identifying rheumatoid arthritis (RA) early—promptly referring patients to a rheumatologist for confirmation and treatment and monitoring both the musculoskeletal and nonmusculoskeletal aspects of the disease. This activity reviews the early symptoms and signs of RA, describes the roles of new and emerging disease-modifying antirheumatic drugs, and offers practical advice on long-term management, with a focus on following for extra-articular manifestations and comorbidities.
Clinical review and case study
After completing this activity, participants should be better able to:
- Assess patients for signs and symptoms of RA
- Identify novel therapies for RA and their appropriate use in clinical practice
- Evaluate patients with RA for extra-articular manifestations and comorbidities
NPs and PAs
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
PA course advisor: Susan M. Tiso, DNP, APRN, FNP-B of University of California, Irvine, Irvine, California
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until October 30, 2021. PAs should only claim credit commensurate with the extent of their participation.
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
This activity was developed from a series of programs cosupported by educational grants from AbbVie Inc.; Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC; Genentech, a member of the Roche Group; Novo Nordisk Inc.; Sanofi Genzyme; and Sanofi Genzyme and Regeneron Pharmaceuticals.
This activity is supported by an educational grant from AbbVie Inc. and Sanofi Genzyme.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange are required to disclose to the audience any relevant support or substantial relationships with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and planning committee have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Mr Pope has no relevant financial relationships to disclose.
None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- Read the content in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 70%.
The estimated time to complete this activity is 1.00 hour.
Release date: October 31, 2020
Expiration date: October 30, 2021
© 2021 Practicing Clinicians Exchange. All Rights Reserved. 97220CPCE-7E